載入中
NASDAQHealthcareBiotechnology
最新資料
US$2.52
−US$0.12 · -4.55%
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
收盤時
US$2.52
−US$0.12 · -4.55%
盤中時間採用ET。市場資料可能有所延遲。
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
日內區間
目前US$2.52
52週區間
目前US$2.52
盤中時間採用ET。市場資料可能有所延遲。
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
日內區間
目前US$2.52
52週區間
目前US$2.52
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 6742.5萬 USD | — | — | — |
| 毛利 | — | 6742.5萬 USD | — | — | — |
| 研究與開發 | 1.07億 USD | 1.68億 USD | 2.35億 USD | 1.73億 USD | 1.76億 USD |
| 銷售、一般及管理費用 | 3771.7萬 USD | 8711.5萬 USD | 5939.8萬 USD | 5455.3萬 USD | 4094.1萬 USD |
| 營業費用 | 1.53億 USD | 2.59億 USD | 3億 USD | 2.27億 USD | 2.17億 USD |
| 利息收入 | — | — | — | 2262 USD | — |
| 利息支出 | — | — | — | 257.5萬 USD | — |
| 折舊和攤銷 | 73.9萬 USD | 128.9萬 USD | 138.9萬 USD | 142.6萬 USD | 54.4萬 USD |
| 營業利益 | −1.53億 USD | −1.91億 USD | −3億 USD | −2.27億 USD | −2.17億 USD |
| 淨利 | −1.37億 USD | −1.66億 USD | −2.92億 USD | −2.37億 USD | −1.59億 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.67
上漲空間 204.37%價格歷史記錄不可用
最高：US$10.00平均的：US$7.67最低：US$5.00報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1074.23萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM349.56萬0.00%787.4億 USD0.19%US$277.88-0.38%
Vanguard Extended Market ETFVXF216.52萬0.00%954億 USD0.05%US$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM159.41萬0.02%64.1億 USD0.28%US$45.24-0.48%
Vanguard Russell 2000 ETFVTWO108.49萬0.01%180億 USD0.06%US$112.27-0.35%
Vanguard Health Care ETFVHT84.03萬0.00%220億 USD0.09%US$320.67+0.52%
Federated Hermes MDT Small Cap Core ETFFSCC69.44萬0.16%4.24億 USD0.50%US$33.93-0.21%
Dimensional - US Small Cap ETFDFAS61.78萬0.00%338.69億 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTFederated Hermes MDT Small Cap Core ETFFSCCDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
